Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs
Authors: Lauren A. Canary, R. Monina Klevens, Scott D. Holmberg
Journal: Annals of Internal Medicine (2015)

Ideas and Opinions4 August 2015Limited Access to New Hepatitis C Virus Treatment Under State Medicaid ProgramsLauren A. Canary, MPH, R. Monina Klevens, DDS, MPH, and Scott D. Holmberg, MD, MPHLauren A. Canary, MPHFrom Centers for Disease Control and Prevention, Atlanta, Georgia., R. Monina Klevens, DDS, MPHFrom Centers for Disease Control and Prevention, Atlanta, Georgia., and Scott D. Holmberg, MD, MPHFrom Centers for Disease Control and Prevention, Atlanta, Georgia.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-0320 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The burden of fatal liver disease is increasing in the estimated 3.2 million adults chronically infected with hepatitis C virus (HCV) in the United States (1–3). Sofosbuvir (Sovaldi, Gilead Sciences), which was approved by the U.S. Food and Drug Administration in December 2013, is a new oral HCV treatment that, when combined with other therapies, has a therapeutic efficacy (cure) greater than 90% across the 4 major HCV genotypes, limited adverse effects, and a shorter treatment window (usually 12 weeks) than its interferon-based predecessors (4). However, this drug currently retails at $84 000 per patient, forcing many payers to ration this ...References1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. [PMID: 24737271] doi:10.7326/M13-1133 LinkGoogle Scholar2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-8. [PMID: 22351712] doi:10.7326/0003-4819-156-4-201202210-00004 LinkGoogle Scholar3. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859-61. [PMID: 23675657] doi:10.1056/NEJMp1302973 CrossrefMedlineGoogle Scholar4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87. [PMID: 23607594] doi:10.1056/NEJMoa1214853 CrossrefMedlineGoogle Scholar5. Kim WR, Gross JB, Poterucha JJ, Locke GR, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology. 2001;33:201-6. [PMID: 11124837] CrossrefMedlineGoogle Scholar6. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62-72. [PMID: 24468275] doi:10.1016/j.antiviral.2014.01.002 CrossrefMedlineGoogle Scholar7. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61:1860-9. [PMID: 25677072] doi:10.1002/hep.27736 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Lauren A. Canary, MPH; R. Monina Klevens, DDS, MPH; Scott D. Holmberg, MD, MPHAffiliations: From Centers for Disease Control and Prevention, Atlanta, Georgia.Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.Acknowledgment: The authors thank Cecily Campbell, JD, LLM (ORISE Fellow, Division of Viral Hepatitis, Centers for Disease Control and Prevention), and the Center for Health Law and Policy Innovation at Harvard Law School for providing their expert knowledge of Medicaid law and structure.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0320.Corresponding Author: Lauren A. Canary, MPH, Division of Viral Hepatitis, National Foundation for the Centers for Disease Control and Prevention, Mailstop G-37, Atlanta, GA 30329; e-mail, lcanary@cdc.gov.Current Author Addresses: Ms. Canary: Division of Viral Hepatitis, National Foundation for the Centers for Disease Control and Prevention, Mailstop G-37, Atlanta, GA 30329.Dr. Klevens: Centers for Disease Control and Prevention, 12 Corporate Square Boulevard, Atlanta, GA 30329.Dr. Holmberg: Division of Viral Hepatitis, Mailstop G-37, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333.Author Contributions:Conception and design: L.A. Canary.Analysis and interpretation of the data: L.A. Canary, M. Klevens, S.D. Holmberg.Drafting of the article: L.A. Canary, S.D. Holmberg.Critical revision of the article for important intellectual content: M. Klevens, S.D. Holmberg.Final approval of the article: M. Klevens, S.D. Holmberg.Obtaining of funding: M. Klevens, S.D. Holmberg.Administrative, technical, or logistic support: S.D. Holmberg.Collection and assembly of data: L.A. Canary.This article was published online first at www.annals.org on 30 June 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRestrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States Soumitri Barua , Robert Greenwald , Jason Grebely , Gregory J. Dore , Tracy Swan , and Lynn E. Taylor Hepatitis C Virus Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction Elinore F. McCance-Katz and Ronald O. Valdiserri Metrics Cited byTelemonitoring of the Continuum of Care of Hepatitis C During the COVID-19 Pandemic in BrazilOpportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus TreatmentUptake of hepatitis C virus treatment in a multi‐state Medicaid population, 2013–2017Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular CarcinomaRapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized TrialHepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central CaliforniaSustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment AccessThe impact of COVID-19 on the cascade of care of HCV in the US and ChinaHepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014–2018Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis CImpact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York CityPrevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency DepartmentPredictors of progression through the cascade of care to a cure for hepatitis C patients using decision trees and random forestsDirect‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis CCommercial insurance delays direct‐acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipientsPatients with hepatocellular carcinoma from more rural and lower‐income households have more advanced tumor stage at diagnosis and significantly higher mortalityManagement of Hepatitis C Viral Infection in People Who Inject DrugsLow Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical dataDeaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016–2017Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfectionAssociation of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis CAssociation of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare BeneficiariesA Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C InfectionA Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence PopulationSutton's Law, Substance Use Disorder, and Treatment of Hepatitis C in the Era of Direct-acting AntiviralsThe Growing Problem of Hepatitis C Virus InfectionEffectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System PerspectiveCost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugsRacial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health AdministrationBarriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral EraA Cost Reimbursement Model for Hepatitis C Treatment Care CoordinationStrategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment CapacityEffective and efficient care delivery for HCV treatments in MedicaidHepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in SeattleThe Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South TexasSofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct‐Acting‐Antiviral Period?Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approachRace/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatmentHepatitis C Management Simplification From Test to Cure: A Framework for Primary Care ProvidersEffect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US VeteransUptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015Time Requirements for Acquisition of Hepatitis C Virus Therapy in HIV/HCV Coinfected PatientsA comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyMedicaid Eligibility Expansions May Address Gaps In Access To Diabetes MedicationsDisparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured PopulationIncreasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral eraStrategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United StatesEstimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic ModelingState Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort StudyDirect-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort studyThe Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and InterventionsChronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapyCost Effectiveness of Pre– vs Post–Liver Transplant Hepatitis C Treatment With Direct-Acting AntiviralsScaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemicRacial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in MedicareReproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected WomenSystematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid PatientsAssessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis CHepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disordersState HCV Incidence and Policies Related to HCV Preventive and Treatment Services For Persons Who Inject Drugs — United States, 2015–2016Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral EraDirect-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-SavingValue of Comprehensive HCV Treatment among Vulnerable, High-Risk PopulationsMedicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis CContinuum of Care for Hepatitis C Virus Among Patients Diagnosed in the Emergency Department SettingMedical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus InfectionRestrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus EthicsState HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs — United States, 2015–2016Registro e incorporação de tecnologias no SUS: barreiras de acesso a medicamentos para doenças da pobreza?Liver Disease and Fibrosis Assessment in Substance Use-Related DisordersHealth Insurance and Coverage of Evidence-Based CareThe Shift in Emphasis From Risk-Based to Age-Based Hepatitis C Virus (HCV) Testing in the US Tends to Remove Injection Drug Use From Discourse on HCVConceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention ContinuaRisk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort StudyFrequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort StudyOn-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trialReal-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4The Burden of Hepatitis C Infection–Related Liver Fibrosis in the United StatesFibrosis Progression in Patients With Chronic Hepatitis C Virus InfectionUse of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIVAccess to treatment for hepatitis C virus infection: time to put patients firstIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureStemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of PhysiciansHilary Daniel, BS, for the Health and Public Policy Committee of the American College of Physicians*Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of InsuranceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataBarriers to Treatment among New York City Residents with Chronic Hepatitis C Virus Infection, 2014The American College of Preventive Medicine Position Statement on Hepatitis C Virus InfectionCost‐effectiveness of new antiviral regimens for treatment‐naïve U.S. veterans with hepatitis CRole of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus InfectionSimple, Effective, but Out of Reach? Public Health Implications of HCV DrugsReply to Messori 4 August 2015Volume 163, Issue 3Page: 226-228KeywordsAlcoholsDrugsHepatitisInfectious diseasesLiver diseasesLiver fibrosisPatientsPrevention, policy, and public healthTreatment guidelinesViral diseases ePublished: 4 August 2015 Issue Published: 4 August 2015 PDF downloadLoading ...